STRYKER RONDA E sold $117.8M of SYK (indirect holdings)

STRYKER RONDA E sold 350,000 indirectly-held shares of STRYKER CORP (SYK) at an average of $336.50 ($331.74–$343.47, $117.78M total) across 20 trades over 2026-08-18 to 2026-08-19.

Original reporting
SEC EDGAR · STRYKER RONDA E
Published Aug 20, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Bearish
high confidence
Mentioned
$SYK
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKBearishMed
01

Why it matters

The disclosed sale may trigger short‑term selling pressure, but the long‑term impact depends on subsequent company performance.

02

Market read

First‑time disclosure of a large insider sale; traders may adjust positions in SYK.

03

What to watch

Potential tax planning or diversification motives for the director, not necessarily bearish sentiment.

Relevance 8/10Novelty 8/10Timing: post‑filing 2026‑08‑20

Background

Form 4 filings disclose insider transactions; a director’s sale of over $100M is noteworthy for traders.

Company-level read

Ticker impact

$SYKBearishHigh confidence
Context

Director Ronda E. Stryker sold 350,000 shares for $117.8M, reducing her stake to 2.25M shares.

Expected impact

Potential short‑term pressure on SYK price, especially if market perceives the sale as a lack of confidence.

Evidence & confidence

The transaction size ($118M) is material for a mid‑cap medical‑device company and is disclosed for the first time via a Form 4.

Market effects

May prompt scrutiny of other medical‑device stocks for similar insider activity.

Limited to U.S. equities; no broader regional effect.

Low; impact confined to SYK and its sector.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Ronda E. Stryker

    Director of Stryker Corp who sold $117.8M of stock.

  • Stryker Corp

    Medical‑device manufacturer (ticker SYK).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

$SYKHighAI 8/10

Stifel cuts Stryker stock price target on weak quarter, guidance

Stifel reduced its price target for Stryker (NYSE:SYK) to $325 from $330, maintaining a Buy rating after the company's Q3 results missed expectations. Stryker reported Q3 sales of $6.52B, below estimates, and lowered its full-year organic sales growth guidance to 6.5-7.0%. Multiple analysts have revised earnings downward, citing execution issues and market slowdowns.

$SYKHighAI 8/10

Stryker Earnings Call Balances Growth With Caution

Stryker Corp (SYK) reported Q3 earnings with 7.7% organic sales growth, 10.3% adjusted EPS increase to $3.52, and margin expansion. Growth was led by MedSurg and Neurotechnology, while Orthopaedics faced challenges. Management highlighted strong capital demand, innovation pipeline, and M&A activity, but acknowledged hip and knee market slowdowns and execution issues.